November 30, 2015

Click Here to Download the Full Report

Despite considerable investments in supply chain reforms, wide-spread medicines stock outs negatively constrain patients’ ability to have access to their medication. Limited availability of antiretroviral drugs (ARVs) caused by dysfunctional supply chains impedes patient initiation and adherence and poses a major barrier to win the global fight against HIV.

Despite the fact that many Zimbabweans risk their lives to flee Zimbabwe, the South African government has historically characterised them as ‘voluntary economic migrants’ and aggressively deported them. Zimbabweans say they had little choice but to leave and thousands continue to cross the border every day, legally and illegally, as a matter of survival.

Over three million people living with HIV/AIDS in the developing world receive antiretroviral therapy (ART). However, the medicines and diagnostic tools available are inadequate to respond fully to their needs. In addition, seven million people are in need of treatment and are still waiting for access.

Today, the good news is that four million HIV-positive people are alive on antiretroviral therapy (ART). The bad news is that MSF teams working to treat HIV/AIDS are witnessing worrying signs of waning international support to combat HIV/AIDS.